Your browser doesn't support javascript.
loading
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.
Hekele, Armin; Bertholet, Sylvie; Archer, Jacob; Gibson, Daniel G; Palladino, Giuseppe; Brito, Luis A; Otten, Gillis R; Brazzoli, Michela; Buccato, Scilla; Bonci, Alessandra; Casini, Daniele; Maione, Domenico; Qi, Zhi-Qing; Gill, John E; Caiazza, Nicky C; Urano, Jun; Hubby, Bolyn; Gao, George F; Shu, Yuelong; De Gregorio, Ennio; Mandl, Christian W; Mason, Peter W; Settembre, Ethan C; Ulmer, Jeffrey B; Craig Venter, J; Dormitzer, Philip R; Rappuoli, Rino; Geall, Andrew J.
Afiliación
  • Hekele A; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Bertholet S; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Archer J; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Gibson DG; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Palladino G; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Brito LA; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Otten GR; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Brazzoli M; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Buccato S; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Bonci A; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Casini D; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Maione D; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Qi ZQ; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Gill JE; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Caiazza NC; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Urano J; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Hubby B; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Gao GF; Chinese Center for Disease Control and Prevention , Beijing 102206, China.
  • Shu Y; Chinese Center for Disease Control and Prevention , Beijing 102206, China.
  • De Gregorio E; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Mandl CW; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Mason PW; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Settembre EC; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Ulmer JB; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Craig Venter J; Synthetic Genomics, Inc., La Jolla, CA 92037, USA.
  • Dormitzer PR; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
  • Rappuoli R; Novartis Vaccines and Diagnostics , Siena 53100, Italy.
  • Geall AJ; Novartis Vaccines and Diagnostics , Cambridge, MA 02139, USA.
Emerg Microbes Infect ; 2(8): e52, 2013 Aug.
Article en En | MEDLINE | ID: mdl-26038486
The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of next generation vaccine technologies for more rapid responses. The SAM(®) vaccine platform, now in pre-clinical development, is based on a synthetic, self-amplifying mRNA, delivered by a synthetic lipid nanoparticle (LNP). When used to express seasonal influenza hemagglutinin (HA), a SAM vaccine elicited potent immune responses, comparable to those elicited by a licensed influenza subunit vaccine preparation. When the sequences coding for the HA and neuraminidase (NA) genes from the H7N9 influenza outbreak in China were posted on a web-based data sharing system, the combination of rapid and accurate cell-free gene synthesis and SAM vaccine technology allowed the generation of a vaccine candidate in 8 days. Two weeks after the first immunization, mice had measurable hemagglutinin inhibition (HI) and neutralizing antibody titers against the new virus. Two weeks after the second immunization, all mice had HI titers considered protective. If the SAM vaccine platform proves safe, potent, well tolerated and effective in humans, fully synthetic vaccine technologies could provide unparalleled speed of response to stem the initial wave of influenza outbreaks, allowing first availability of a vaccine candidate days after the discovery of a new virus.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Emerg Microbes Infect Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Emerg Microbes Infect Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos